Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2007 1
2008 1
2009 4
2010 2
2011 3
2012 1
2013 3
2014 2
2015 2
2016 2
2017 4
2018 1
2020 3
2021 6
2022 4
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Theragnostic in neuroendocrine tumors.
Marini I, Sansovini M, Bongiovanni A, Nicolini S, Grassi I, Ranallo N, Monti M, DI Iorio V, Germanò L, Caroli P, Sarnelli A, Paganelli G, Severi S. Marini I, et al. Among authors: sansovini m. Q J Nucl Med Mol Imaging. 2021 Dec;65(4):342-352. doi: 10.23736/S1824-4785.21.03426-9. Epub 2021 Dec 9. Q J Nucl Med Mol Imaging. 2021. PMID: 34881852
Radioligand therapies in cancer: mapping the educational landscape in Europe.
Bugani V, Battistelli L, Sansovini M, Monti M, Paganelli G, Gich I, Flotats A, Erba PA, Blay JY, la Fougère C, Van Poppel H, Charalambous A, Herrmann K, Giordano A, Györke T, Deroose C, Matteucci F, Carrió I. Bugani V, et al. Among authors: sansovini m. Eur J Nucl Med Mol Imaging. 2023 Jul;50(9):2692-2698. doi: 10.1007/s00259-023-06217-0. Epub 2023 Apr 14. Eur J Nucl Med Mol Imaging. 2023. PMID: 37058168 Free PMC article.
Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma.
Lechner M, Takahashi Y, Turri-Zanoni M, Liu J, Counsell N, Hermsen M, Kaur RP, Zhao T, Ramanathan M Jr, Schartinger VH, Emanuel O, Helman S, Varghese J, Dudas J, Riechelmann H, Sprung S, Haybaeck J, Howard D, Engel NW, Stewart S, Brooks L, Pickles JC, Jacques TS, Fenton TR, Williams L, Vaz FM, O'Flynn P, Stimpson P, Wang S, Hannan SA, Unadkat S, Hughes J, Dwivedi R, Forde CT, Randhawa P, Gane S, Joseph J, Andrews PJ, Royle G, Franchi A, Maragliano R, Battocchio S, Bewicke-Copley H, Pipinikas C, Webster A, Thirlwell C, Ho D, Teschendorff A, Zhu T, Steele CD, Pillay N, Vanhaesebroeck B, Mohyeldin A, Fernandez-Miranda J, Park KW, Le QT, West RB, Saade R, Manes RP, Omay SB, Vining EM, Judson BL, Yarbrough WG, Sansovini M, Silvia N, Grassi I, Bongiovanni A, Capper D, Schüller U, Thavaraj S, Sandison A, Surda P, Hopkins C, Ferrari M, Mattavelli D, Rampinelli V, Facchetti F, Nicolai P, Bossi P, Henriquez OA, Magliocca K, Solares CA, Wise SK, Llorente JL, Patel ZM, Nayak JV, Hwang PH, Lacy PD, Woods R, O'Neill JP, Jay A, Carnell D, Forster MD, Ishii M, London NR Jr, Bell DM, Gallia GL, Castelnuovo P, Severi S, Lund VJ, Hanna EY. Lechner M, et al. Among authors: sansovini m. Eur J Cancer. 2022 Feb;162:221-236. doi: 10.1016/j.ejca.2021.09.046. Epub 2021 Dec 31. Eur J Cancer. 2022. PMID: 34980502 Free PMC article.
HRAS overexpression predicts response to Lenvatinib treatment in gastroenteropancreatic neuroendocrine tumors.
Liverani C, Spadazzi C, Ibrahim T, Pieri F, Foca F, Calabrese C, De Vita A, Miserocchi G, Cocchi C, Vanni S, Ercolani G, Cavaliere D, Ranallo N, Chiadini E, Prisinzano G, Severi S, Sansovini M, Martinelli G, Bongiovanni A, Mercatali L. Liverani C, et al. Among authors: sansovini m. Front Endocrinol (Lausanne). 2023 Jan 20;13:1045038. doi: 10.3389/fendo.2022.1045038. eCollection 2022. Front Endocrinol (Lausanne). 2023. PMID: 36743926 Free PMC article.
177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study.
Paganelli G, Sansovini M, Nicolini S, Grassi I, Ibrahim T, Amadori E, Di Iorio V, Monti M, Scarpi E, Bongiovanni A, Altini M, Urso L, Cittanti C, Matteucci F, Severi S. Paganelli G, et al. Among authors: sansovini m. Eur J Nucl Med Mol Imaging. 2021 Jan;48(1):152-160. doi: 10.1007/s00259-020-04873-0. Epub 2020 May 29. Eur J Nucl Med Mol Imaging. 2021. PMID: 32472437 Clinical Trial.
177Lu-DOTATATE Efficacy and Safety in Functioning Neuroendocrine Tumors: A Joint Analysis of Phase II Prospective Clinical Trials.
Bongiovanni A, Nicolini S, Ibrahim T, Foca F, Sansovini M, Di Paolo A, Grassi I, Liverani C, Calabrese C, Ranallo N, Matteucci F, Paganelli G, Severi S. Bongiovanni A, et al. Among authors: sansovini m. Cancers (Basel). 2022 Dec 7;14(24):6022. doi: 10.3390/cancers14246022. Cancers (Basel). 2022. PMID: 36551507 Free PMC article.
Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors.
Nicolini S, Bodei L, Bongiovanni A, Sansovini M, Grassi I, Ibrahim T, Monti M, Caroli P, Sarnelli A, Diano D, Di Iorio V, Grana CM, Cittanti C, Pieri F, Severi S, Paganelli G. Nicolini S, et al. Among authors: sansovini m. Eur J Nucl Med Mol Imaging. 2021 Sep;48(10):3260-3267. doi: 10.1007/s00259-021-05236-z. Epub 2021 Feb 18. Eur J Nucl Med Mol Imaging. 2021. PMID: 33604690 Free PMC article. Clinical Trial.
Prognostic and Predictive Role of Body Composition in Metastatic Neuroendocrine Tumor Patients Treated with Everolimus: A Real-World Data Analysis.
Ranallo N, Iamurri AP, Foca F, Liverani C, De Vita A, Mercatali L, Calabrese C, Spadazzi C, Fabbri C, Cavaliere D, Galassi R, Severi S, Sansovini M, Tartaglia A, Pieri F, Crudi L, Bianchini D, Barone D, Martinelli G, Frassineti GL, Ibrahim T, Calabrò L, Berardi R, Bongiovanni A. Ranallo N, et al. Among authors: sansovini m. Cancers (Basel). 2022 Jun 30;14(13):3231. doi: 10.3390/cancers14133231. Cancers (Basel). 2022. PMID: 35805003 Free PMC article.
34 results